News Search Results
Jan 28, 2026, 16:01 ET AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Jan 28, 2026, 09:15 ET Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
fundamentals strengthen. This structural shift creates a window for Oncolytics Biotech Inc. (NASDAQ: ONCY), BioNTech (NASDAQ: BNTX), MAIA Biotechnology (NYSE-A: MAIA), Acrivon Therapeutics (NASDAQ: ACRV), and ImmunityBio (NASDAQ: IBRX).
More news about: USA News Group
Jan 28, 2026, 09:03 ET GenScript is Scripting Possibilities in AI-Driven Drug Discovery as Wet-Lab Partner for Latent-X2 Innovation
real-world drug candidates with unprecedented speed and precision.""GenScript is dedicated to catalysing the next generation of AI-first biotechnology," said Dr. Ray Chen, President of GenScript Life Science Group. "With the launch of Latent-X2, we are demonstrating how high-throughput wet-lab
More news about: GenScript USA
Jan 28, 2026, 08:30 ET Subsidiary of Pinnacle Food Group Limited Enters into Biotechnology Research Collaboration Agreement
subsidiary, Pinnacle Food AgTech HK Limited, has entered into a research and technology collaboration agreement with Bioboost Synbio Consulting Inc., a biotechnology consulting company based in Vancouver, Canada.
More news about: Pinnacle Food Group Limited
Jan 28, 2026, 07:43 ET CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease
improving the bioavailability of small-molecule drugs.A Nano-Scale "Medicinal Guide": Reimagining Curcumin with Modern BiotechnologyAcademician Dr. Lin Jaung-Geng of Academia Sinica explained that curcumin, long revered in traditional medicine as a "food-medicine homolog,"
More news about: China Medical University Hospital
Jan 28, 2026, 07:30 ET REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
which has been shown to correlate with neurocognitive manifestations of the disorder.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jan 28, 2026, 06:30 ET Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Jan 28, 2026, 06:00 ET Danaher Reports Fourth Quarter and Full Year 2025 Results
December 31, 2025 ($14 million pretax as reported in this line item, $11 million after-tax), technology, other intangible assets and a facility in the Biotechnology segment recorded in the year ended December 31, 2025 ($101 million pretax as reported in this line item, $69 million after-tax), a trade name in
More news about: Danaher Corporation
Jan 28, 2026, 05:30 ET First Mold's U.S. Mold Exports Rise 30% in 2025, Driven by Electronics, Automotive, and Medical Manufacturing Demand
9.8 %Medical and biotechnology8.5 %
More news about: First Mold
Jan 27, 2026, 14:05 ET Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
/PRNewswire/ -- Anchor Line Partners, LLC and Northwood Investors, LLC announced today that they have secured a significant long-term lease with biotechnology company Stoke Therapeutics (Nasdaq: STOK) at 245 Fifth Avenue in Waltham, Massachusetts. Stoke plans to relocate to its new 98,500 square-foot headquarters
More news about: Anchor Line Partners
Jan 27, 2026, 13:09 ET MILLROCK TECHNOLOGY APPOINTS TOM HOCHULI AS CEO
team"Most recently, Mr. Hochuli served as President of a biologics-focused organization delivering cellular materials and end-to-end services to biotechnology and biopharmaceutical customers. In that role, he led a comprehensive operational and strategic transformation, improving financial performance,
More news about: Artemis
Jan 27, 2026, 12:44 ET Rubin Rudman Partner Julayne Lazar Joins Boston Cares Board of Directors
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Jan 27, 2026, 11:29 ET Nuveen Green Capital and Brandywine Realty Trust Close Largest C-PACE Financing in Pennsylvania History
"This investment affirms our shared commitment to growing Philadelphia as a world-class hub for growth industries, especially our life sciences and biotechnology sectors."Completed and ready for occupancy, 3151 Market is Philadelphia's next-generation innovation building, meticulously designed with
More news about: Nuveen Green Capital
Jan 27, 2026, 11:00 ET IP Attorney John Paik Joins Crowell & Moring's Patents Group
Paik joins Crowell from GRAIL, a biotechnology company, where he served as senior director and head of intellectual property. He led the protection of the company's wet lab discoveries and its
More news about: Crowell & Moring LLP
Jan 27, 2026, 10:55 ET Medical Plastic Compounds Market Surges to USD 15.8 Billion by 2033, Propelled by 5.1% CAGR - Verified Market Reports®
Kit Market Size By Product Type (PCR-Based Kits, ELISA Kits), By Application (Agricultural Testing, Food Testing), By End-User (Chemical And Biotechnology Companies, Academic And Research Institutions), By Technology (Molecular Biology Techniques, Immunological Techniques), By Distribution Channel
More news about: Verified Market Reports
Jan 27, 2026, 10:50 ET Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
asymmetric investment window for Oncolytics Biotech Inc. (NASDAQ: ONCY), Moderna (NASDAQ: MRNA), Merck (NYSE: MRK), Vir Biotechnology (NASDAQ: VIR), and Coherus Oncology (NASDAQ: CHRS) at the intersection of pivotal execution readiness and combination immunotherapy innovation
More news about: Equity Insider
Jan 27, 2026, 10:50 ET Global Poria Cocos Extract Market Shows Strong Momentum Driven by Natural Health Trends: - Market Research Intellect
Co., Ltd., Xi'an Greena Biotech Co., Ltd., Shaanxi Jintai Biological Engineering Co., Ltd., Changsha Huir Biological-Tech Co., Ltd., Nutra Green Biotechnology Co., Ltd., and Herblink BiotechSEGMENTS
More news about: Market Research Intellect
Jan 27, 2026, 10:48 ET /C O R R E C T I O N -- BridGene Biosciences/
patients and generate substantial value in the biopharmaceutical field."About BridGene BiosciencesBridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets. Leveraging its
More news about: BridGene Biosciences
Jan 27, 2026, 10:03 ET Top Cancer Researchers Join Forces to Advance Development of Therapeutic Cancer Vaccines
diagnosed with cancer in our lifetime, there's no time to waste."The think tank brings together leaders from top academic cancer centers, biotechnology and pharmaceutical companies, as well as policy and regulatory experts to establish shared priorities and actionable strategies to accelerate cancer
More news about: Cancer Vaccine Coalition
Jan 27, 2026, 10:01 ET Proteomics Market worth $65.78 Billion by 2030 | MarketsandMarkets™
in 2024.North America represents the largest regional market for proteomics. The large share is supported by the strong presence of biotechnology and pharmaceutical companies, along with sustained R&D spending across discovery and translational programs. The region also benefits from a
More news about: MarketsandMarkets
Jan 27, 2026, 09:00 ET Debut Unveils Biotech Active Delivering In-Office Skin Tightening Results in Topical Skincare
Powered by AI, skin genomics and biotechnology, Debut developed DermCeutical EDL™, the first-ever topical ingredient clinically proven to tighten and firm skin for a visibly lifted appearance.SAN DIEGO, Jan. 27,
More news about: Debut Biotechnology
Jan 27, 2026, 09:00 ET Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its
More news about: Insilico Medicine
Jan 27, 2026, 08:30 ET Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued a
More news about: Anixa Biosciences, Inc.
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets, today announces positive results from the nine month interim
More news about: Skyhawk Therapeutics
Jan 27, 2026, 08:00 ET Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets, today announces positive results from the nine month interim
More news about: Skyhawk Therapeutics